Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells.
It has been demonstrated that potassium channels (K(+) channels) play significant roles in some malignant phenotypes. Here, we provide the first evidence that treatment with glybenclamide, an ATP-sensitive K(+) channel blocker, inhibited cell migration in an ovarian clear cell carcinoma cell line, ES-2. Treatment with glybenclamide or knockdown by siRNA targeted against K(+) channel subunits demonstrated the suppression of ovarian cancer cell invasion, which occurred via inhibition of PDGF-AA secretion. Therefore, our findings suggest that K(+) channel blockers may be useful chemotherapeutic drugs for blocking the invasiveness of ovarian cancers.
Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.
Tamami
T
Yasukagawa
Yuki
Y
Niwa
Siro
S
Simizu
Kazuo
K
Umezawa
D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005905:Glyburide / Q000494:pharmacology*; D006801:Humans; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016133:Polymerase Chain Reaction; D026902:Potassium Channel Blockers / Q000494:pharmacology
D010982:Platelet-Derived Growth Factor; D026902:Potassium Channel Blockers; D005905:Glyburide